Status:
COMPLETED
Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus
Lead Sponsor:
Resolve Therapeutics
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
A one month multi-dose study will evaluate the safety and tolerability of 3 intravenous infusions of RSLV-132 in subjects with inactive to mild SLE.
Eligibility Criteria
Inclusion
- Stable SLE with no anticipated change in medications for the next 60 days
Exclusion
- Other biologic drugs
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT02194400
Start Date
July 1 2014
End Date
November 1 2015
Last Update
December 9 2015
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research of West Florida
Clearwater, Florida, United States, 33765
2
West Michigan Rheumatology
Grand Rapids, Michigan, United States, 49546
3
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
4
Metroplex Clinical Research
Dallas, Texas, United States, 75231